167 related articles for article (PubMed ID: 22904129)
1. CK5, CK5/6, and double-stains CK7/CK5 and p53/CK5 discriminate in situ vs invasive urothelial cancer in the prostate.
Fichtenbaum EJ; Marsh WL; Zynger DL
Am J Clin Pathol; 2012 Aug; 138(2):190-7. PubMed ID: 22904129
[TBL] [Abstract][Full Text] [Related]
2. Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases.
Osunkoya AO; Epstein JI
Am J Surg Pathol; 2007 Sep; 31(9):1323-9. PubMed ID: 17721186
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma.
Kunju LP; Mehra R; Snyder M; Shah RB
Am J Clin Pathol; 2006 May; 125(5):675-81. PubMed ID: 16707367
[TBL] [Abstract][Full Text] [Related]
4. Primary seminal vesicle carcinoma: an immunohistochemical analysis of four cases.
Ormsby AH; Haskell R; Jones D; Goldblum JR
Mod Pathol; 2000 Jan; 13(1):46-51. PubMed ID: 10658909
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma.
Mhawech P; Uchida T; Pelte MF
Hum Pathol; 2002 Nov; 33(11):1136-40. PubMed ID: 12454820
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
7. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma.
Genega EM; Hutchinson B; Reuter VE; Gaudin PB
Mod Pathol; 2000 Nov; 13(11):1186-91. PubMed ID: 11106075
[TBL] [Abstract][Full Text] [Related]
8. Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia.
Aron M; Luthringer DJ; McKenney JK; Hansel DE; Westfall DE; Parakh R; Mohanty SK; Balzer B; Amin MB
Am J Surg Pathol; 2013 Dec; 37(12):1815-23. PubMed ID: 24225842
[TBL] [Abstract][Full Text] [Related]
9. Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma.
Bassily NH; Vallorosi CJ; Akdas G; Montie JE; Rubin MA
Am J Clin Pathol; 2000 Mar; 113(3):383-8. PubMed ID: 10705819
[TBL] [Abstract][Full Text] [Related]
10. The role of immunohistochemistry in the diagnosis of flat urothelial lesions: a study using CK20, CK5/6, P53, Cd138, and Her2/Neu.
Jung S; Wu C; Eslami Z; Tanguay S; Aprikian A; Kassouf W; Brimo F
Ann Diagn Pathol; 2014 Feb; 18(1):27-32. PubMed ID: 24321464
[TBL] [Abstract][Full Text] [Related]
11. Utility of D2-40, Cytokeratin 5/6, and High-Molecular-weight Cytokeratin (Clone 34βE12) in Distinguishing Intraductal Spread of Urothelial Carcinoma From Prostatic Stromal Invasion.
Iakymenko OA; Briski LM; Delma KS; Jorda M; Kryvenko ON
Am J Surg Pathol; 2022 Apr; 46(4):454-463. PubMed ID: 34560681
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical staining patterns of Ki-67 and p53 in florid reactive urothelial atypia and urothelial carcinoma in situ demonstrate significant overlap.
Nguyen JK; Przybycin CG; McKenney JK; Magi-Galluzzi C
Hum Pathol; 2020 Apr; 98():81-88. PubMed ID: 32142835
[TBL] [Abstract][Full Text] [Related]
13. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens.
McKenney JK; Desai S; Cohen C; Amin MB
Am J Surg Pathol; 2001 Aug; 25(8):1074-8. PubMed ID: 11474293
[TBL] [Abstract][Full Text] [Related]
14. Flat Intraurothelial Neoplasia Exhibiting Diffuse Immunoreactivity for CD44 and Cytokeratin 5 (Urothelial Stem Cell/Basal Cell Markers): A Variant of Intraurothelial Neoplasia Commonly Associated With Muscle-invasive Urothelial Carcinoma.
Mai KT; Busca A; Belanger EC
Appl Immunohistochem Mol Morphol; 2017 Aug; 25(7):505-512. PubMed ID: 26990746
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases.
Oliva E; Pinheiro NF; Heney NM; Kaufman DS; Shipley WU; Gurski C; Spicer B; Paner GP; Gown AM; Amin MB
Hum Pathol; 2013 May; 44(5):860-6. PubMed ID: 23199526
[TBL] [Abstract][Full Text] [Related]
16. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
Epstein JI; Egevad L; Humphrey PA; Montironi R;
Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
[TBL] [Abstract][Full Text] [Related]
17. Nested and microcystic variants of urothelial carcinoma displaying immunohistochemical features of basal-like urothelial cells: an immunohistochemical and histopathogenetic study.
Mai KT; Hakim SW; Ball CG; Flood TA; Belanger EC
Pathol Int; 2014 Aug; 64(8):375-81. PubMed ID: 25143125
[TBL] [Abstract][Full Text] [Related]
18. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
Tamas EF; Epstein JI
Am J Surg Pathol; 2007 Mar; 31(3):390-7. PubMed ID: 17325480
[TBL] [Abstract][Full Text] [Related]
19. Utility of cytokeratin 5/6, cytokeratin 20, and p16 in the diagnosis of reactive urothelial atypia and noninvasive component of urothelial neoplasia.
Edgecombe A; Nguyen BN; Djordjevic B; Belanger EC; Mai KT
Appl Immunohistochem Mol Morphol; 2012 May; 20(3):264-71. PubMed ID: 22498670
[TBL] [Abstract][Full Text] [Related]
20. Utility of uroplakin II expression as a marker of urothelial carcinoma.
Tian W; Guner G; Miyamoto H; Cimino-Mathews A; Gonzalez-Roibon N; Argani P; Li X; Sharma R; Subhawong AP; Rezaei K; Bivalacqua TJ; Epstein JI; Bishop JA; Netto GJ
Hum Pathol; 2015 Jan; 46(1):58-64. PubMed ID: 25449628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]